No Data
Maxim Group Maintains CNS Pharmaceuticals(CNSP.US) With Buy Rating, Maintains Target Price $10
CNS Pharmaceuticals Reports Q1 EPS ($7.30) Vs. ($18.93) Last Year
CNS Pharmaceuticals Sees Cash Runway 'Beyond' Twelve Months
Express News | CNS Pharmaceuticals Q1 EPS $(7.30) Misses $(5.37) Estimate
CNS Pharmaceuticals Reports Q1 Results
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress